tandem stock price target
Analyst estimates including TNDM earnings per share estimates and analyst recommendations. TNDM Complete Tandem Diabetes Care Inc.
2 Stocks Oppenheimer Sees Surging Over 80
Find the latest Tandem Diabetes Care Inc.
. Wuensch cited market multiples are contracting due to higher inflation slowing growth and rising interest rates. TNDM stock quote history news and other vital information to help you with your stock trading and investing. Stock Price Forecast The 12 analysts offering 12-month price forecasts for Tandem Diabetes Care Inc have a median target of 13000 with a high estimate of 20000 and a.
Our Tandem Diabetes Care Inc stock price forecast data is based on consensus analyst prediction covering public companies earnings per. The price target was changed from 10420 to 184. TANDEM DIABETES CARE INC.
Learn more on TNDMs analyst rating history. TNDM Analyst Price Target. TNDM have crossed above the average analyst 12-month target price of 10527 changing hands for 10541share.
See Tandem Diabetes Care Inc. TNDM Nasdaq. On average analysts rate TNDM stock as a buy.
Over the last 90 days this security got 1 buy 2 sell and 0 hold ratings. And BofA Securities analyst Travis Steed reinstated coverage on Tandem Diabetes Care NASDAQ. Find the latest Tandem Group TND stock price forecast 12-month price target predictions and analyst recommendations.
To contextualize these metrics consider that out of all US stocks Tandem Diabetes Care Incs average analyst price target is higher than 10468 of them. The Tandem Diabetes Care NASDAQ. TNDM shares have received a 130 price target from BofA Securities.
TNDM stock analyst estimates including earnings and revenue EPS upgrades and downgrades. Citigroup reduced their target price on Tandem Diabetes Care from 16300 to 15500 and set a buy rating for the company in a research note on Wednesday February 23rd. Tandem Diabetes Care Inc.
The average twelve-month price prediction for Tandem Diabetes Care is 14300 with a high price target of 20000 and a low price target of 12000. When a stock reaches. And And Citi analyst Joanne Wuensch is maintaining a Buy rating on the shares.
TNDM with a Neutral rating. According to data from MarketBeat Tandem Diabetes Care currently has a consensus rating of Buy and a consensus price target of 13980. SVB Leerink Adjusts Tandem Diabetes Cares Price Target to 110 from 120.
Tandem Diabetes Care alerts. Lowering target price to 6900. The medical devices company also raised its sales outlook for 2019 to 300 million to.
Oppenheimer Adjusts Tandem Diabetes Care Price Target to 130 From 142 Maintains Outp. Stock news by MarketWatch. Stock Price Forecast.
The last rating was given by Citigroup on Feb 23 2022. Lichtman has an outperform rating and an 80 price target on Tandem stock. Tandem Diabetes current and average target prices are 7001 and 13350 respectively.
40 rows Tandem Diabetes Care Stock Forecast NASDAQTNDM Price Target and Analyst Ratings. What is TNDMs Earnings Per Share EPS forecast for 2022-2023. TNDM stock forecast based on top analysts estimates plus more investing and trading data from Yahoo Finance.
Shares of TNDM stock. The shares of Tandem Diabetes Care Inc NASDAQ. According to 19 stock analysts the average 12-month stock price forecast for TNDM stock is 14144 which predicts an increase of 10748.
Wells Fargo Company boosted their price target on Tandem Diabetes Care from 16000 to 16600 and gave the company an overweight rating in a research note on Wednesday February 23rd. Find the latest Tandem Diabetes Care Inc. In recent trading shares of Tandem Diabetes Care Inc Symbol.
View real-time stock prices and stock quotes for a full financial overview. Stock quote stock chart quotes analysis advice financials and news for share TANDEM DIABETES CARE INC. TNDM have received a 130 price target from Citi.
The current price of Tandem Diabetes is the price at which Tandem Diabetes Care is currently trading. TNDM has a higher upside potential average analyst target price relative to current price than 14996 of Healthcare stocks. Finally Wells Fargo Company upped their price target on Tandem Diabetes Care from 16000 to 16600 and gave the stock an overweight rating in a research note on Wednesday February 23rd.
5 Wall Street analysts that have issued a 1 year TNDM price target the average TNDM price target is 13380. The average TANDEM DIABETES CARE stock price prediction forecasts a potential upside of 1602 from the current TNDM share price of 11532. But Wuensch does not know how far the derating.
On the other hand Tandem Diabetes target price is what analysts think the stock is worth or could sell for in the future. The lowest target is 101 and the highest is 210.
Tandem Diabetes Bullish As Innovations Capitalize On A Booming Sector Nasdaq Tndm Seeking Alpha
The Top 3 Drivers Of The Stock Bond Correlation And Yes Inflation Is One Of Them Blog Posts Qontigo
Tndm Tandem Diabetes Care Inc Stock Overview U S Nasdaq Barron S
Tndm Tandem Diabetes Care Inc Stock Overview U S Nasdaq Barron S
News Updates From November 5 Pfizer Reveals Upbeat Trial Results For Covid Pill Pelosi Vows To Press Ahead With Vote On Infrastructure Bill Ba Owner Warns Of 3bn Loss In 2021 Financial Times
Tndm Tandem Diabetes Care Inc Stock Overview U S Nasdaq Barron S
Emerging Markets Monitor Archive Lazard Asset Management
Tandem Diabetes Care This Is A Coronavirus Resilient Pick For April 2020 Nasdaq Tndm Seeking Alpha
Tandem Diabetes Care Inc Research Ratings Tndm Barron S
Dow Drops 170 Points As Investors Assess Russia Ukraine Tensions Fed S Plans For Rate Hikes
Keep On Buying These 3 Ev Stocks Says Analyst Following Conference
Tandem Diabetes Care Inc Research Ratings Tndm Barron S
Emerging Markets Monitor Archive Lazard Asset Management
Tandem Diabetes Care Inc Research Ratings Tndm Barron S
Tandem Diabetes Bullish As Innovations Capitalize On A Booming Sector Nasdaq Tndm Seeking Alpha
Tndm Stock Price And Chart Nasdaq Tndm Tradingview
Tandem Diabetes Care Inc Research Ratings Tndm Barron S
2 Strong Buy Stocks Oppenheimer Sees Surging Over 80 Nasdaq
Netflix Is A Great Company But The Stock Is Significantly Overvalued Says Analyst Nasdaq